In today’s briefing:
- Mesoblast (MSB AU): What Lies Ahead After FDA Approval
- Amaero International Ltd – US government loan of IS$23.5m a significant milestone
Mesoblast (MSB AU): What Lies Ahead After FDA Approval
- Mesoblast Ltd (MSB AU) got FDA approval for Ryoncil for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
- Following approval in pediatric patients, Mesoblast intends to commence a Phase 3 trial of Ryoncil in adults and adolescents, which has larger market size.
- FDA approval enhances conviction on the commercial prospect of the other late-stage product candidates of the company, including Revascor for advanced chronic heart failure and rexlemestrocel-L for inflammatory pain indications.
Amaero International Ltd – US government loan of IS$23.5m a significant milestone
- RaaS Research Group has published an update on advanced materials manufacturing group Amaero International (ASX:3DA) following the company’s announcement yesterday that it has secured final approval for a US$23.5m (A$37.8m) loan from the Export-Import Bank of the United States, the US federal government’s export credit agency, under the Make More in America (MMIA) initiative.
- The loan will be drawn against the estimated US$28.5m in capital equipment purchases the company has announced for its Tennessee facility.
- We view this as an important milestone for Amaero as it delivers non-dilutive, US-government funded support to the company on favourable terms.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
